0054-0382 : Cyclophosphamide 25 mg Oral Capsule


NDC: 0054-0382
Labeler: Roxane Laboratories, Inc.
Product Type: Human Prescription Drug
Drug Name:  Cyclophosphamide
Dosage Form: Oral Capsule
Application #: NDA203856
Rev. Date: 


Appearance:


Markings: 54;006
Shapes:  Capsule
Colors:  Blue
Size (mm): 8
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

54 006: (0054-0382) Cyclophosphamide 25 mg Oral Capsule by Roxane Laboratories, Inc.
The above image is provided by the U.S. National Library of Medicine (NLM) and is not part of the official label.

NDC Package Codes:

  • 0054-0382-25: 100 CAPSULE IN 1 BOTTLE (0054‑0382‑25)

Active Ingredients:

  • Cyclophosphamide

Dosage Strength:

  • 25 mg

Inactive Ingredients:

  • Starch, Corn
  • Sodium Stearyl Fumarate
  • Fd&c Blue No. 1
  • Fd&c Red No. 40
  • Gelatin
  • Titanium Dioxide
  • Ammonia
  • Ferrosoferric Oxide
  • Isopropyl Alcohol
  • Butyl Alcohol
  • Propylene Glycol
  • Shellac

Pharmaceutical Classes:

  • Alkylating Activity [MoA]
  • Alkylating Drug [EPC]

Related Products:

Based on records with the same trade name.
  • 0054-0383 Cyclophosphamide 50 mg Oral Capsule by Roxane Laboratories, Inc.
  • 0054-4129 Cyclophosphamide 25 mg Oral Tablet by Roxane Laboratories, Inc
  • 0054-4130 Cyclophosphamide 50 mg Oral Tablet by Roxane Laboratories, Inc
  • 0338-9777 Cyclophosphamide 200 mg/ml Intravenous Injection by Baxter Healthcare Corporation
  • 0338-9779 Cyclophosphamide 200 mg/ml Intravenous Injection by Baxter Healthcare Corporation
  • 0781-3233 Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Sandoz Inc.
  • 0781-3244 Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Sandoz Inc.
  • 0781-3255 Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Sandoz Inc.
  • 0781-3528 Cyclophosphamide 500 mg/5ml Intravenous Injection, Solution, Concentrate by Sandoz Inc
  • 0781-3529 Cyclophosphamide 1000 mg/10ml Intravenous Injection, Solution, Concentrate by Sandoz Inc
  • 0781-3530 Cyclophosphamide 2000 mg/20ml Intravenous Injection, Solution, Concentrate by Sandoz Inc
  • 10019-935 Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-936 Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-937 Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-938 Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-939 Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-942 Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-943 Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-944 Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-945 Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • More related products ...

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 0054-0382 QR Code

< Prev: 0054-0379Next: 0054-0383 >

Related Discussions:

greyhound cyclophosphamide with pirixicam cyl hycl 100 cap
My Greyhound Cut his Foot And He Takes Cyclophosphamide 17 Mg With Pirixicam 11 mg once A Day with food. I Want To Know ...




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.